RT Journal Article
SR Electronic
T1 Detection of precancerous gastric lesions and gastric cancer through exhaled breath
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 400
OP 407
DO 10.1136/gutjnl-2014-308536
VO 65
IS 3
A1 Amal, Haitham
A1 Leja, Marcis
A1 Funka, Konrads
A1 Skapars, Roberts
A1 Sivins, Armands
A1 Ancans, Guntis
A1 Liepniece-Karele, Inta
A1 Kikuste, Ilze
A1 Lasina, Ieva
A1 Haick, Hossam
YR 2016
UL http://gut.bmj.com/content/65/3/400.abstract
AB Objectives Timely detection of gastric cancer (GC) and the related precancerous lesions could provide a tool for decreasing both cancer mortality and incidence.Design 968 breath samples were collected from 484 patients (including 99 with GC) for two different analyses. The first sample was analysed by gas chromatography linked to mass spectrometry (GCMS) while applying t test with multiple corrections (p value<0.017); the second by cross-reactive nanoarrays combined with pattern recognition. For the latter, 70% of the samples were randomly selected and used in the training set while the remaining 30% constituted the validation set. The operative link on gastric intestinal metaplasia (OLGIM) assessment staging system was used to stratify the presence/absence and risk level of precancerous lesions. Patients with OLGIM stages III–IV were considered to be at high risk.Results According to the GCMS results, patients with cancer as well as those at high risk had distinctive breath-print compositions. Eight significant volatile organic compounds (p value<0.017) were detected in exhaled breath in the different comparisons. The nanoarray analysis made it possible to discriminate between the patients with GC and the control group (OLGIM 0–IV) with 73% sensitivity, 98% specificity and 92% accuracy. The classification sensitivity, specificity, and accuracy between the subgroups was as follows: GC versus OLGIM 0–II—97%, 84% and 87%; GC versus OLGIM III–IV—93%, 80% and 90%; but OLGIM I–II versus OLGIM III–IV and dysplasia combined—83%, 60% and 61%, respectively.Conclusions Nanoarray analysis could provide the missing non-invasive screening tool for GC and related precancerous lesions as well as for surveillance of the latter.Trial registration number Clinical Trials.gov number, NCT01420588 (3/11/2013).